Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis
Author(s) -
Maysoon Elkhawad,
James H.F. Rudd,
Lea SarovBlat,
Gengqian Cai,
R. J. Wells,
Ceri Davies,
David Collier,
Michael Marber,
Robin P. Choudhury,
Zahi A. Fayad,
Ahmed Tawakol,
Fergus Gleeson,
John J. Lepore,
Bill Davis,
Robert N. Willette,
Ian B. Wilkinson,
Dennis L. Sprecher,
Joseph Cheriyan
Publication year - 2012
Publication title -
jacc. cardiovascular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.79
H-Index - 120
eISSN - 1936-878X
pISSN - 1876-7591
DOI - 10.1016/j.jcmg.2012.02.016
Subject(s) - medicine , placebo , inflammation , fluorodeoxyglucose , c reactive protein , positron emission tomography , clinical endpoint , confidence interval , p38 mitogen activated protein kinases , statin , gastroenterology , cardiology , protein kinase a , randomized controlled trial , kinase , pathology , nuclear medicine , alternative medicine , biology , microbiology and biotechnology
This study sought to determine the effects of a p38 mitogen-activated protein kinase inhibitor, losmapimod, on vascular inflammation, by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography imaging.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom